Track topics on Twitter Track topics that are important to you
The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.
Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.
Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.
Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Phone: 39 0521 2791
Fax: 39 0521 774468
Privately-held Italian drugmaker Chiesi Farmaceutici has been publicly reprimanded for providing inaccurate…
After struggling to bring the product to market on its own, Pharmaxis Ltd. secured Chiesi Farmaceutici SPA as its exclusive US partner for the cystic fibrosis candidate Bronchitol (mannitol), which is...
Chiesi made its sales reps go through a ‘tick-box’ compliance training exercise to get the pharma industry regulator ‘off its back’ – according to a public reprimand by the industry standard...
Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The PMCPA notes that misleading claims regarding Fostair (formoterol/beclometas...
Dr Andreas Chiesi, CEO, Holostem Terapie Avanzate S.r.l
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Fostair (beclometasone/formoterol; Chiesi) inhaler for patients with chronic obstruct...
Further supply issues for Ventmax (salbutamol sulphate; Chiesi) SR capsules 4mg and 8mg mean that the products will not be back in stock before September 2015.
CUROSURF (poractant alfa)Intratracheal Suspension
Multiple organ failure and pancreatic necrosis are the factors that determine prognosis in acute pancreatitis attacks. We investigated the effects of collagenase on the debridement of experimental pan...
Group-based emotions are emotional reactions to group concerns and have been shown to emerge when people appraise events while endorsing a specific social identity. Here we investigate whether discuss...
Objective: The aim of this study was to investigate the imaging assessment of interspinous ligament degeneration (ISLD) in patients with or without low back pain (LBP). Methods: Sixty patients with LB...
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...
The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...
Assessing OCD before and after group therapy
All parents in Sweden are offered group based parental support within Child Health Service (CHS) but only 40% participate. Nurses feel insecure in their group leadership and express a need...
This is an observational clinical study, patients with systemic diseases will be enrolled according to the inclusion and exclusion criteria. 360 patients will received the examination of s...
The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...
Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...
W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...
PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...
Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...
We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.
Latest News Clinical Trials Research Drugs Reports Corporate
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...